Earlier this month, the Centers for Medicare and Medicaid Services (CMS) released the final “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary” rule (42 CFR Part 405).
CLSA issued a statement after the issuance of the Most Favored Nation (MFN) Interim Final Rule, and our subsequent legal action we have joined with our partners BIO and Biocom.
In September, the Centers for Medicare and Medicaid Services (CMS) released a proposed rule (CMS-3372-P) entitled “Medicare Coverage of Innovative Technology (MCIT) and Definition of ‘Reasonable and Necessary’”.
The new Fiscal Year (FY) will begin at midnight tonight on October 1st. At the time this update was prepared on September 29th, a government shutdown is unlikely following the House passage of a continuing resolution (CR) to fund the government at FY20 levels through December 11, 2020.
CLSA is profoundly disappointed by the Administration’s decision to move forward with the flawed concept of a ‘Most Favored Nation’ policy that threatens the innovative life sciences ecosystem and patient access to cutting edge biomedical advancement.
CLSA has long supported efforts to combat AMR, and in a continuation of efforts to expand the coalition of organizations that CLSA engages with on important issues, we agreed to join 14 other cosigners on the letters.
President Trump officially signed four Executive Orders (EOs) last Friday. The EOs target four policy areas: drug importation, 340B, rebate rule, and most concerning – IPI/Most Favored Nation (MFN).
California Life Sciences Association president and CEO Mike Guerra issued the following statement about the scheduled vote on H.R. 1425, the Patient Protection and Affordable Care Enhancement Act.
After a decade of vocal opposition, Congress finally fully and permanently repealed the 2.3% excise tax on medical devices.
House overwhelmingly passes year-end spending deal that includes a permanent repeal of the 2.3% medical device tax, Senate likely to approve